3392-12-9

Basic information

• Product Name: tert-Butoxycarbonyl-L-valine N-hydroxysuccinimide ester
• Synonyms: BOC-L-VALINE HYDROXYSUCCINIMIDE ESTER;BOC-L-VALINE N-HYDROXYSUCCINIMIDE ESTER;BOC-VAL-OSU;BOC-VALINE-OSU;N-ALPHA-T-BOC-L-VALINE N-HYDROXYSUCCINIMIDE ESTER;N-BOC-L-VAL-N-HYDROXYSUCCINIMIDE;N-TERT-BUTOXYCARBONYL-L-VALINE-N-HYDROXYSUCCINIMIDE ESTER;tert-butyl (S)-[1-[[(2,5-dioxopyrrolidin-1-yl)oxy]carbonyl]-2-methylpropyl]carbamate
• CAS NO: 3392-12-9
• Molecular Formula: C₁₄H₂₂N₂O₆
• Molecular Weight: 314.33
• EINECS: 222-236-5
• Product Categories: Amino Acid Derivatives;Amino Acid
• Mol File: 3392-12-9.mol
• Article Data: 24

Chemical Properties

• Melting Point: 126-128 °C
• Appearance: White to off-white/Powder
• Density: 1.223 g/cm³
• Refractive Index: 1.505
• Storage Temp.: −20°C
• PKA: 10.72±0.46(Predicted)
• Sensitive: Moisture Sensitive
• BRN: 1551859
• CAS DataBase Reference: tert-Butoxycarbonyl-L-valine N-hydroxysuccinimide ester(CAS DataBase Reference)
• NIST Chemistry Reference: tert-Butoxycarbonyl-L-valine N-hydroxysuccinimide ester(3392-12-9)
• EPA Substance Registry System: tert-Butoxycarbonyl-L-valine N-hydroxysuccinimide ester(3392-12-9)

Safety Data

• WGK Germany: 3
• F: 3-10-21
• Hazardous Substances Data: 3392-12-9(Hazardous Substances Data)

Usage

Chemical Properties

White powder

InChI:InChI=1/C14H22N2O6/c1-8(2)11(15-13(20)21-14(3,4)5)12(19)22-16-9(17)6-7-10(16)18/h8,11H,6-7H2,1-5H3,(H,15,20)

Upstream product

• 6066-82-6 1-hydroxy-pyrrolidine-2,5-dione 
• 13734-41-3 t-Boc-L-valine 
• 96935-01-2 Isopropenyl Succinimido Carbonate 
• 107960-02-1 1,2,2,2-tetrachloroethyl-(N-succinimidyl)carbonate 
• 72-18-4 L-valine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 13734-41-3 (tert-butoxycarbonyl)-L-valine 

Downstream Products

• 72635-99-5 4-((S)-2-{4-[(S)-2-((S)-2-tert-Butoxycarbonylamino-3-methyl-butyrylamino)-3-methyl-butyrylamino]-3-hydroxy-butyrylamino}-propionylamino)-3-hydroxy-butyric acid 4-nitro-benzyl ester 
• 69209-72-9 (N-tert-butoxycarbonyl-L-valyl)-L-valine 
• 108334-64-1 N-tert-butyloxycarbonyl-L-valyl-L-phenylalanine 
• 86624-62-6 (S)-2-((S)-2-tert-Butoxycarbonylamino-3-methyl-butyrylamino)-5-formylamino-pentanoic acid; compound with dicyclohexyl-amine 
• 33956-18-2 Boc-Val-Lys(Z)-OMe 
• 142811-54-9 ((S)-1-{3,5-Bis-[((S)-2-tert-butoxycarbonylamino-3-methyl-butyrylamino)-methyl]-benzylcarbamoyl}-2-methyl-propyl)-carbamic acid tert-butyl ester 
• 108305-07-3 N^α-t-butyloxycarbonyl-L-valyl-O-acetyl-L-tyrosine 
• 67106-22-3 tert-butyl (S)-1-(benzylamino)-3-methyl-1-oxobutan-2-ylcarbamate 
• 88489-22-9 Boc-L-Val-L-Orn(Z)-L-Leu-OMe 
• 102991-95-7 Boc-Val-Val-Gly-OPac 
• 138850-76-7 Boc-Val-Glu(OBzl)-Glu(OBzl)-Lys(Z)-Ala-Gly-OBzl 
• 111854-54-7 Boc-Val-Gly-Ser(Bzl)-Glu(OBzl)-Ala-Phe-NH₂ 
• 128090-88-0 Boc-Val-Val-Phe-OH 
• 5519-69-7 Boc-Val-Orn(Z)-Leu-D-Phe-Pro-OH 

Relevant articles and documents

2-AMINO-N-(AMINO-OXO-ARYL-LAMBDA6-SULFANYLIDENE)ACETAMIDE COMPOUNDS AND THEIR THERAPEUTIC USE

The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain 2-amino-N-(amino-oxo-aryl-λ6- sulfanylidene)acetamide compounds (referred to herein as ANASIA compounds) that, inter alia, inhibit (e.g., selectively inhibit) bacterial aminoacyl-tRNA synthetase (aaRS) (e.g., bacterial leucyl-tRNA synthetase, LeuRS). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit (e.g., selectively inhibit) bacterial aminoacyl-tRNA synthetase; to treat disorders that are ameliorated by the inhibition (e.g., selective inhibition) of bacterial aminoacyl-tRNA synthetase; to treat bacterial infections; etc.

An optimal “Click” formulation strategy for antibody-drug conjugate synthesis

As a versatile reaction for bioconjugation, Cu(I)-catalyzed alkyne-azide cycloaddition (CuAAC) has enormous potential in the synthesis of antibody-drug conjugates (ADCs). In order to optimize CuAAC-based ADC synthesis, we characterized kinetically different formulation processes by mimicking ADC synthesis using small molecules and subsequently revealed unique kinetic behaviors of different combinations of alkyne and azide conditions. Our results indicate that under ADC synthesis conditions, for an alkyne-containing drug, its concentration has minimal impact on the reaction rate when an antibody has a non-metal-chelating azide but is proportional to concentration when an antibody contains a metal-chelating azide; however, for an alkyne-containing antibody, the ADC synthesis rate is proportional to the concentration of a drug with a non-metal-chelating azide but displays almost no dependence on drug concentration with a metal-chelating azide. Based on our results, we designed and tested an optimal “click” formulation strategy that allowed rapid and cost-effective synthesis of a new ADC.

MAYTANSINOID DERIVATIVES, CONJUGATES THEREOF, AND METHODS OF USE

Provided herein are maytansinoid derivatives, conjugates thereof, and methods of treating or preventing proliferative diseases with the same.